

Human-Associated Extended-Spectrum β -Lactamase in the Antarctic

Jorge Hernández,^{a,b} Johan Stedt,^b Jonas Bonnedahl,^{b,c} Ylva Molin,^a Mirva Drobni,^a Nancy Calisto-Ulloa,^d Claudio Gomez-Fuentes,^d M. Soledad Astorga-España,^d Daniel González-Acuña,^e Jonas Waldenström,^b Maria Blomqvist,^b and Björn Olsen^{a,b}

Uppsala University, Uppsala, Sweden^a; Linnaeus University, Kalmar, Sweden^b; Kalmar County Hospital, Kalmar, Sweden^c; University of Magallanes, Punta Arenas, Chile^d; and University of Concepcion, Chillán, Chile^e

***Escherichia coli* bacteria with extended-spectrum β -lactamase (ESBL) type CTX-M resistance were isolated from water samples collected close to research stations in Antarctica. The isolates had *bla*_{CTX-M-1} and *bla*_{CTX-M-15} genotypes and sequence types (ST) indicative of a human-associated origin. This is the first record of ESBL-producing enterobacteria from Antarctica.**

Enterobacteriaceae with extended-spectrum β -lactamase (ESBL) enzymes are increasing in clinical and veterinary medicine, posing a threat to future health care (6). ESBL-producing bacteria are now commonly isolated both in industrialized and in developing countries (6, 12), and dissemination into the environment has been observed (1). The most common ESBLs are TEM, SHV and CTX-M—each with a different evolutionary origin (4, 9). These classes are subdivided into gene groups, and to date >300 different ESBL variants have been described (8). In recent years, CTX-M has become the most widespread class (5). The Antarctic continent is the last comparatively pristine ecosystem, with a small human population restricted to research bases, primarily located on the Antarctic Peninsula. Human activities are regulated by the Antarctic Treaty to reduce interference with the unique wildlife, and the impact of human-associated microorganisms should be minimal (2). However, contrary to this intention, human-associated pathogens have been identified in Antarctic wildlife (18). Here we report the presence of human-associated ESBL-producing *Escherichia coli* with *bla*_{CTX-M} genes in water sampled close to research bases on the Antarctic Peninsula and the South Shetland Islands, providing the first cases of ESBL found in the region.

The fieldwork was conducted during the 2011 austral summer (January–February), when the bases Bernardo O’Higgins on the Antarctic Peninsula, the Fildes Bay (King George Island), and the Arturo Prat (Greenwich Island) in the South Shetland Islands were visited for sampling. Water samples were collected from the sea surface in concentric circles from the stations’ sewage outlets (10, 25, 50, 100, 200, and 300 m). Each of the 123 water samples (125-ml volume) was filtered through sterile 0.45- μ m-pore-size membrane filters and were cultured on chromogenic selective plates (ChromoCult, Merck, Darmstadt, Germany) for detection of *E. coli* and coliform flora. The filters were then placed in Luria broth [phosphate-buffered saline including 0.45% Na citrate, 0.1% MgSO₄, 1% (NH₄)₂SO₄, and 4.4% glycerol] and stored at –70°C. Additionally, we sampled a total of 400 fresh fecal droppings from gentoo penguins (*Pygoscelis papua*) from colonies close to the bases. All samples were shipped on dry ice to Sweden for further analyses.

In order to isolate *E. coli* for characterization, all water and penguin feces samples were cultivated on Uriselect4 plates (Bio-Rad Laboratories Ltd., Hemel Hempstead, United King-

dom) and colonies were identified by conventional biochemical tests. A total of 71 *E. coli* isolates (40 from water and 31 from penguin samples) were randomly chosen to determine antibiotic susceptibility profiles using the EUCAST disk diffusion method in order to receive an overall picture of resistance in the material (15). The panel included 11 antibiotic disks: tetracycline, 30 μ g/disk; ampicillin, 10 μ g/disk; streptomycin, 10 μ g/disk; chloramphenicol, 30 μ g/disk; nalidixic acid, 30 μ g/disk; cefadroxil, 30 μ g/disk; fosfomicin, 50 μ g/disk; tigecycline, 15 μ g/disk; trimethoprim-sulfamethoxazole, 1.25/23.75 μ g/disk; nitrofurantoin, 100 μ g/disk; and amdinocillin, 10 μ g/disk (all antibiotics from Oxoid Ltd., Cambridge, United Kingdom). The *E. coli* strain ATCC 25922 was used as a control.

Only one *E. coli* isolate from a penguin (Bernardo O’Higgins base) had a resistant phenotype, in this case to chloramphenicol. In the water samples, three isolates were resistant to at least one antibiotic compound and several were resistant to two or more antibiotics (Table 1). The most frequently observed resistance was to ampicillin, found in 11 isolates, followed by tetracycline (6 isolates), streptomycin (4 isolates), and trimethoprim-sulfamethoxazole (4 isolates). One *E. coli* isolate was resistant to nalidixic acid (Table 1). The presence of ESBL-producing bacteria was investigated by enriching all samples in brain heart infusion broth (Becton Dickinson, Franklin Lakes, NJ) supplemented with vancomycin (16 mg/liter; ICN Biomedicals Inc. Aurora, OH) for 18 h at 37°C and subsequently inoculating them on chromID ESBL plates (bioMérieux, Marcy L’Etoile, France). Ten *E. coli* ESBL isolates were retrieved, and ESBL production was confirmed in each isolate with a cefpodoxime/cefepodoxime + clavulanic acid double-disk test (MAST Diagnostics, Bootle, United Kingdom). These isolates were all positive for the CTX-M ESBL but negative for TEM and SHV in specific quantitative PCR (qPCR) (13, 14). The PCR products were sequenced on both strands using the following primers: CTX-F (5’-TCCCAGAATAAGGAATCCCAT-3’) and CTX-R1 (5’-CCCATTCCGTTTCCGCTA-3’). The re-

Received 27 October 2011 Accepted 23 December 2011

Published ahead of print 13 January 2012

Address correspondence to Jorge Hernández, Jorge.hernandez@lnu.se.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AEM.07320-11

TABLE 1 Numbers of resistant *E. coli* isolates from seawater samples collected at three research bases in the Antarctic region, 2011

Antibiotic compound or description	No. of <i>E. coli</i> isolates per location		
	Greenwich Island	Antarctic Peninsula	King George Island
Nalidixic acid	0	0	1
Streptomycin	1	1	2
Tetracycline	5	0	1
Ampicillin	7	2	2
Trimethoprim-sulfamethoxazole	1	1	2
Susceptible to all compounds	0	8	20
Resistant to 1 compound	1	1	1
Resistant to 2 compounds	5	0	0
Resistant to 3 compounds	1	1	1
Resistant to 4 compounds	0	0	1

sulting consensus sequences were compared with published sequences in the NCBI database. Four *E. coli* isolates, all from Fildes Bay, carried the *bla*_{CTX-M-1} gene, while six isolates (four from Arturo Prat and two from Bernardo O'Higgins) carried the *bla*_{CTX-M-15} gene. The ESBL isolates were further analyzed by multilocus sequencing typing (MLST) using a modified version of previously described procedures (19). Sequence types (STs) and putative associated sources were retrieved from an on-line MLST *E. coli* database (<http://mlst.ucc.ie/mlst/dbs/Ecoli/>). Six different STs (ST131, ST227, ST401, ST410, ST685, and ST937), two to four at each research station, were identified (Table 2).

The *bla*_{CTX-M-1} and *bla*_{CTX-M-15} genes are both human-associated ESBL genotypes (16, 19). Genotyping by MLST corroborated the association with human gastrointestinal biota, as the majority of the STs belonged to widespread disease-associated genotypes, including *E. coli* ST131 carrying the *bla*_{CTX-M-15} gene, a worldwide disseminated human clinical clone (11). These findings constitute the first records of ESBL-producing bacteria in Antarctica, and given that they were isolated from all the sampled bases it seems that human-associated bacteria are discharged into the environment more than occasionally. The emergence of CTX-M has been referred to as one of the most striking examples of rapid, global dissem-

ination of plasmid-mediated resistance determinants among bacterial pathogens (16). Nosocomial and community spread of ESBL genotypes is well described in humans (3), but there are fewer studies of the presence of these genes in bacteria in the environment (1). The efforts to suppress further development and dispersal of resistance are focused on reducing the consumption of antibiotics. However, the factors that maintain and perhaps facilitate further resistance dispersal in natural environments (e.g., sewage treatment) are given less attention. The mechanisms behind the success of CTX-M are still to be determined (16). Therefore, the finding of CTX-M-producing bacteria in Antarctic seawater and the finding of a high prevalence of CTX-M in certain wild bird populations need to be considered carefully. In addition to ESBL-producing isolates, several non-ESBL *E. coli* isolates with resistance to common antibiotics were found in the water samples, including isolates with resistance to up to four compounds (Table 1). An important question to ask is whether the human-associated bacteria found close to human activities infect Antarctic wildlife. None of the sampled penguins were positive for ESBL-producing bacteria, and only one *E. coli* isolate exhibited antibiotic resistance, indicating that at the time of sampling, human-associated enterobacteriaceae were not common in the sampled penguins. The risk to a bird of being colonized by *E. coli* has been shown to vary with the proximity to environments influenced by human activity (10). An earlier study in Antarctica indicated a 17% prevalence of *E. coli* in penguins (17). The lower prevalence of *E. coli* (~8%) in our samples could indicate infrequent interactions between penguin and human microbiota, especially since the penguin strains were highly susceptible to antibiotics and showed no presence of ESBL. However, penguins are but one part of the ecosystem, and compared to more opportunistic feeders, such as kelp gulls (*Larus dominicanus*), skuas (*Stercorarius* spp.), and snowy sheathbills (*Chionis albus*), they may be less exposed to human-associated bacteria. An opportunistic diet has previously been associated with the presence of human-associated enteropathogens in birds (7). At present, we cannot tell whether ESBL-producing bacteria are present in Antarctic wildlife or what consequences that would have for animal health. However, the presence of anthropo-

TABLE 2 Genotypic and phenotypic characteristics of ESBL-producing *E. coli* isolates from water samples collected at three research bases in the Antarctic region, 2011

Location	Isolate	ESBL genotype ^a	MLST		Phenotypic resistance(s) ^b
			ST	Clonal complex	
Greenwich Island	1	CTX-M-15	ST410	ST23 complex	Na, Tet, Amp, Cfr
	2	CTX-M-15	ST410	ST23 complex	Na, Tet, Amp, Cfr
	3	CTX-M-15	ST410	ST23 complex	Na, Tet, Amp, Cfr
	4	CTX-M-15	ST685	Unassigned	Na, Amp, Cfr
Antarctic Peninsula	1	CTX-M-15	ST937	Unassigned	Na, Tet, Amp, Cfr
	2	CTX-M-15	ST131	Unassigned	Na, Tet, Amp, Cfr
King George Island	1	CTX-M-1	ST401	Unassigned	Amp, Cfr
	2	CTX-M-1	ST131	Unassigned	Amp, Cfr
	3	CTX-M-1	ST410	ST23 complex	Amp, Cfr
	4	CTX-M-1	ST227	ST10 complex	Amp, Cfr

^a None of the isolates were found to have TEM or SHV ESBL genotypes.

^b Na, nalidixic acid; Tet, tetracycline; Amp, ampicillin; Cfr, cefadroxil.

genic bacteria in the Antarctic environment is worrisome in itself and indicative of how widespread the global antibiotic resistance situation has become. The existing precautions and sewage treatment at the research bases seem inadequate. Clearly, increased sampling in the Antarctic biome is warranted, as well as increased efforts in reducing potential leakage of bacteria from human activities.

ACKNOWLEDGMENTS

This study benefitted from logistical support from Instituto Antártico Chileno (projects T09-08 and T27-10). Additional funding was given by grants from the Swedish Research Foundation FORMAS (2008-326) and the Swedish Research Council (VR).

REFERENCES

- Bonnedahl J, et al. 2009. Dissemination of *Escherichia coli* with CTX-M type ESBL between humans and yellow-legged gulls in the south of France. *PLoS One* 4:e5958.
- Bonnedahl J, et al. 2008. Antibiotic susceptibility of faecal bacteria in Antarctic penguins. *Polar Biol.* 31:759–763.
- Canton R, Coque TM. 2006. The CTX-M beta-lactamase pandemic. *Curr. Opin. Microbiol.* 9:466–475.
- Chong Y, Ito Y, Kamimura T. 2011. Genetic evolution and clinical impact in extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*. *Infect. Genet. Evol.* 11:1499–1504.
- Coque TM, et al. 2008. Dissemination of clonally related *Escherichia coli* strains expressing extended-spectrum beta-lactamase CTX-M-15. *Emerg. Infect. Dis.* 14:195–200.
- Dancer SJ. 2001. The problem with cephalosporins. *J. Antimicrob. Chemother.* 48:463–478.
- Dolejska M, Cizek A, Literak I. 2007. High prevalence of antimicrobial-resistant genes and integrons in *Escherichia coli* isolates from Black-headed gulls in the Czech Republic. *J. Appl. Microbiol.* 103:11–19.
- Dropa M, et al. 2009. Extended-spectrum beta-lactamases among *Enterobacteriaceae* isolated in a public hospital in Brazil. *Rev. Inst. Med. Trop. Sao Paulo.* 51:203–209.
- Gniadkowski M. 2001. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. *Clin. Microbiol. Infect.* 7:597–608.
- Gordon DM, Cowling A. 2003. The distribution and genetic structure of *Escherichia coli* in Australian vertebrates: host and geographic effects. *Microbiology* 149:3575–3586.
- Hernandez J, et al. 2010. Globally disseminated human pathogenic *Escherichia coli* of O25b-ST131 clone, harbouring blaCTX-M-15, found in Glaucous-winged gull at remote Commander Islands, Russia. *Environ. Microbiol. Rep.* 2(2):329–332.
- Moreno A, Bello H, Guggiana D, Dominguez M, Gonzalez G. 2008. Extended-spectrum beta-lactamases belonging to CTX-M group produced by *Escherichia coli* strains isolated from companion animals treated with enrofloxacin. *Vet. Microbiol.* 129:203–208.
- Pitout JD, Hossain A, Hanson ND. 2004. Phenotypic and molecular detection of CTX-M-beta-lactamases produced by *Escherichia coli* and *Klebsiella* spp. *J. Clin. Microbiol.* 42:5715–5721.
- Pitout JD, et al. 1998. β -Lactamases responsible for resistance to expanded-spectrum cephalosporins in *Klebsiella pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* isolates recovered in South Africa. *Antimicrob. Agents Chemother.* 42:1350–1354.
- Rodríguez-Baño J, et al. 2011. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β -lactamase-producing *Escherichia coli*. *Clin. Microbiol. Infect.* doi:10.1111/j.1469-0691.2011.03673.x.
- Rossolini GM, D'Andrea MM, Mugnaioli C. 2008. The spread of CTX-M-type extended-spectrum beta-lactamases. *Clin. Microbiol. Infect.* 14(Suppl. 1):33–41.
- Soucek Z, Mushin R. 1970. Gastrointestinal bacteria of certain Antarctic birds and mammals. *Appl. Microbiol.* 20:561–566.
- Vigo GB, et al. 2010. Isolation and characterization of *Salmonella enterica* from Antarctic wildlife. *Polar Biol.* 34:675–681.
- Wirth T, et al. 2006. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol. Microbiol.* 60:1136–1151.